SkyView Investment Advisors’s Biotech Acquisition Company Unit BIOTU Stock Holding History

SkyView Investment Advisors’s Portfolio BIOTU Stock Details BIOTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,183	Closed	-$31K	–	653
2022 Q1	$31K	Hold	3,183	–	–	0.01%	484
2021 Q4	$32K	Buy	+3,183	New	+$32.2K	0.01%	477

Other funds holding BIOTU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SkyView Investment Advisors's BIOTU Position: Q2 2022 in Review

SkyView Investment Advisors sold out of Biotech Acquisition Company Unit (BIOTU) in Q2 2022, closing a stake of 3,183 shares — an estimated $31K sold.

SkyView Investment Advisors first reported a position in BIOTU in Q4 2021 and held it in 2 quarters. The position peaked at $32K in Q4 2021. 5 funds tracked by Wall St. Rank hold BIOTU as of Q2 2022.

SkyView Investment Advisors reported no remaining Biotech Acquisition Company Unit position as of Q2 2022 after selling out during the quarter.
SkyView Investment Advisors sold 3,183 Biotech Acquisition Company Unit shares in Q2 2022, an estimated $31K.
SkyView Investment Advisors first reported a position in Biotech Acquisition Company Unit in Q4 2021 and held it in 2 quarters.
SkyView Investment Advisors's Biotech Acquisition Company Unit position peaked at $32K in Q4 2021.
5 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q2 2022.

Based on SkyView Investment Advisors's 13F filing for Q2 2022, filed 15 Nov 2022.